Selecting Neurologic Function Tests for Parkinson’s Disease: A Primer

  • A. R. Potvin
  • W. W. Tourtellotte
  • G. V. Kondraske
  • K. Syndulko
  • J. H. Potvin
Conference paper


Recent advances in quantitative procedures have greatly enhanced the sensitivity, objectivity, and reliability of neurologic evaluation and diagnosis. Innovative electrophysiologic, radiologic, and biochemical laboratory procedures have proven useful to the clinician, whose traditional evaluation of the patient has been based on inference and indirect evidence of disease processes and pathologies.


Multiple Sclerosis Neurologic Function Instrument Test Total Quality Management Positron Emission Tomograph 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albers JW, Potvin AR, Tourtellotte WW, Pew RW, Stribley RF (1973) Quantification of hand tremor in the clinical neurological examination. IEEE Trans Biomed Eng 20:27–37PubMedCrossRefGoogle Scholar
  2. 2.
    Behbehani K, Kondraske GV, Richmond JR (1988) Investigation of upper extremity visuomotor control performance measures. IEEE Trans Biomed Eng BME-35(7):518–525CrossRefGoogle Scholar
  3. 3.
    Behbehani K, Kondraske GV, Tintner R, Tindall RAS, Imrhan SN (1990) Evaluation of quantitative measures of upper extremity speed and coordination in healthy persons and in three patient populations. Arch Phys Med 71(2):106–111PubMedGoogle Scholar
  4. 4.
    Domino EF, Albers JW, Potvin AR, Repa BS, Tourtellotte WW (1972) Effects of amphetamine on quantitative measures of motor performance. Clin Pharmacol Ther 13(2):251–257PubMedGoogle Scholar
  5. 5.
    Goldratt EM, Cox J (1986) The goal: a process of ongoing improvement. North River, New YorkGoogle Scholar
  6. 6.
    Henderson WG, Tourtellotte WW, Potvin AR (1975) Training examiners to administer a quantitative neurological examination for a multicenter clinical trial. Arch Phys Med Rehabil 56:289–295PubMedGoogle Scholar
  7. 7.
    Henderson WG, Tourtellotte WW, Potvin AR, Rose AS (1978) Methodology for analyzing clinical neurological data: ACTH in multiple sclerosis. Clin Pharmacol Ther 24(2):146–153PubMedGoogle Scholar
  8. 8.
    Imai M (1986) Kaisen: the key to Japan’s competitive success. Random House, New YorkGoogle Scholar
  9. 9.
    Jex HR, McDonnell JD, Phatak AV (1966) A critical tracking task for manual control research. IEEE Trans Hum Fac Eng 7:138CrossRefGoogle Scholar
  10. 10.
    Kelman HR, Willner A (1962) Problems in measurement and evaluation of rehabilitation. Arch Phys Med Rehabil 43:172PubMedGoogle Scholar
  11. 11.
    Kondraske GV (1982) Design, construction, and evaluation of an automated computer-based system for quantification of neurologic function. Thesis, University of Texas, Arlington, TexasGoogle Scholar
  12. 12.
    Kondraske GV (1990) A PC-based performance measurement laboratory system. J Clin Eng 15(6):467–478Google Scholar
  13. 13.
    Kuzma JW, Tourtellotte WW, Remington RD (1965) Quantitative clinical neurological testing. II. Some statistical considerations of a battery of tests. J Chronic Dis 18:305CrossRefGoogle Scholar
  14. 14.
    LaRocca NG, Scheinberg LC, Slater RN, in collaboration with Giesser B, Smith CR, Traugott U, Schapiro RT, Paty DW, Franklin GM, Cobble N, Petejan JH, Kraft GH, Frankél D, Catanzaro M, Poser CM, Tourtellotte WW, Baumhefner RW (1985) Field testing of a minimal record of disability in multiple sclerosis: the United States and Canada. Acta Neurol Scand 70[Suppl 101]:126–138Google Scholar
  15. 15.
    Potvin AR, Tourtellotte WW (1975) The neurological examination: advancements in its quantification. Arch Phys Med Rehabil 56(10):425–437PubMedGoogle Scholar
  16. 16.
    Potvin AR, Tourtellotte WW (1985) Quantitative examination of neurologic functions, vol. I and vol. II CRC Press, Boca Raton, FloridaGoogle Scholar
  17. 17.
    Potvin AR, Tourtellotte WW, Dailey JS, Walker JE, Albers JW, Henderson WG, Snyder DN (1972) Simulated activities of daily living examination. Arch Phys Med Rehabil 53:476–487PubMedGoogle Scholar
  18. 18.
    Potvin AR, Tourtellotte WW, Pew RW, Albers JW, Henderson WG, Snyder DN (1973a) The importance of age effects on performance in the assessment of clinical trials. J Chronic Dis 26:699–717PubMedCrossRefGoogle Scholar
  19. 19.
    Potvin AR, Tourtellotte WW, Pew RW, Albers JW, Henderson WG, Snyder DN (1973b) Motivation and learning in the quantitative examination of neurological function. Arch Phys Med Rehabil 54:432–440PubMedGoogle Scholar
  20. 20.
    Potvin AR, Albers JW, Repa BS, Henderson WG, Walker JE, Stribley RF, Pew RW, Tourtellotte WW (1974) Quantitative evaluation of neuropharmacological trials. Clin Pharmacol Ther 15:229–241PubMedGoogle Scholar
  21. 21.
    Potvin AR, Albers JW, Stribley RF, Tourtellotte WW, Pew RW (1975a) A battery of tests for evaluating steadiness in clinical trials. Med Biol Eng 13:914–922PubMedCrossRefGoogle Scholar
  22. 22.
    Potvin AR, Salamy JG, Crosier WG, Jones KW, Doerr JA (1975b) Effects of secobarbitol on performance upon arousal from stage 4 sleep. Appl Neurophysiol 38:240–250PubMedGoogle Scholar
  23. 23.
    Potvin AR, Tourtellotte WW, Henderson WG, Snyder DN (1975c) Quantitative examination of neurological function: reliability and learning effects. Arch Phys Med Rehabil 56(10):438–442Google Scholar
  24. 24.
    Potvin AR, Tourtellotte WW, Snyder DN, Henderson WG, Albers JW (1975d) Validity of quantitative tests measuring tremor. Am J Phys Med 54(5):243–252PubMedGoogle Scholar
  25. 25.
    Potvin AR, Doerr JA, Estes JT, Tourtellotte WW (1977) A portable clinical tracking task instrument. Med Biol Eng Comput 15:391–397PubMedCrossRefGoogle Scholar
  26. 26.
    Potvin AR, Syndulko K, Tourtellotte WW, Lemmon JA, Potvin JH (1980a) Human neurologic function and the aging process. J Am Geriatr Soc 28(l):l-9Google Scholar
  27. 27.
    Potvin AR, Tourtellotte WW, Syndulko K, Potvin JH, Baumhefner RW (1980b) Multiple sclerosis clinical trials: a comprehensive system for the measurement and evaluation of neurologic function. In: Bauer HJ, Poser S, Ritter G (eds) Progress in multiple sclerosis research. Springer, Berlin Heidelberg New York, pp 603–625Google Scholar
  28. 28.
    Potvin AR, Syndulko K, Tourtellotte WW, Goldberg Z, Potvin JH, Hansch EC (1981a) Quantitative evaluation of normal age-related changes in neurologic function. In: Maletta GJ, Pirozlo FJ (eds) Advances in neurogerontology, vol 2. Praeger, New York, chap 2, pp 13–57Google Scholar
  29. 29.
    Potvin AR, Tourtellotte WW, Syndulko K, Potvin JH (1981b) Quantitative methods in assessment of neurologic function. CRC Crit Rev Bioeng 6(3):177–224Google Scholar
  30. 30.
    Repa BS, Albers JW, Potvin AR, Tourtellotte WW (1971) The use of a battery of tracking tests in the quantitative evaluation of neurological function. In: Proceedings of the 7th annual NASA-University conference on manual control, University of Southern California, NASA-SP, 281:119–123Google Scholar
  31. 31.
    Repa BS, Albers JW, Pew RW, Tourtellotte WW (1972) Clinical applications of tracking. In: Proceedings of the 8th annual University of Michigan-NASA conference on manual controlGoogle Scholar
  32. 32.
    Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW (1968, 1970) Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbations. Preliminary report: Neurology 18(6); final report: Neurology 20(5):Part 2,1Google Scholar
  33. 33.
    Stribley RF, Albers JW, Tourtellotte WW, Cockrell JL (1974) A quantitative study of stance in normal subjects. Arch Phys Med Rehabil 55:74PubMedGoogle Scholar
  34. 34.
    Syndulko K, Tourtellotte WW (1989) Use of a quantitative test battery for long-term evaluation of clinical efficacy in Parkinson’s disease. In: Davis R, Kondraske GV, Tourtellotte WW (eds) Physical medicine and rehabilitation, vol 3/2. Hanley and Belfus, Philadelphia, pp 168–176Google Scholar
  35. 35.
    Tourtellotte WW (1985) Minimal record of disability for multiple sclerosis. National Multiple Sclerosis Society, April 1985Google Scholar
  36. 36.
    Tourtellotte WW, Haerer AF, Simpson JF, Kuzma JW, Sikorski J (1965) Quantitative clinical neurological testing. I. A study of a battery of tests designed to evaluate in part the neurological function of patients with multiple sclerosis and its use in a therapeutic trial. NY Acad Sci 122:480CrossRefGoogle Scholar
  37. 37.
    Tourtellotte WW, Potvin AR, Costanza AM, Hirsch SB, Syndulko K (1978) Cyclobenzaprine: a new type of anti-parkinsonian drug. Prog Neuropsychopharmacol 2(5/6):553–578CrossRefGoogle Scholar
  38. 38.
    Tourtellotte WW, Potvin AR, Mendez M, Baumhefner RW, Potvin JH, Ma BI, Syndulko K (1980a) Failure of intravenous and intrathecal cytarabine to modify central nervous system IgG synthesis in multiple sclerosis. Ann Neurol 8:402–408PubMedCrossRefGoogle Scholar
  39. 39.
    Tourtellotte WW, Syndulko K, Potvin AR, Hirsch SB, Potvin JH (1980b) Increased ratio of carbidopa to levodopa in treatment of Parkinson’s disease. Arch Neurol 37:723–726PubMedGoogle Scholar
  40. 40.
    Tourtellotte WW, Potvin AR, Syndulko K, Hirsch SB, Gilden ER, Potvin JH, Hansch EC (1982) Parkinson’s disease: Cogentin with Sinemet, a better response. Prog Neuropsychopharmacol Biol Psychiatry 6:51–55PubMedCrossRefGoogle Scholar
  41. 41.
    Tourtellotte WW, Syndulko K, Baumhefner RW, Potvin AR (1986) Neuroimmunologic pharmacology of multiple sclerosis. I. A comprehensive protocol for preliminary clinical trials in MS. In: Hommes OR, Mertin J, Tourtellotte WW (eds) Proceedings on immunosuppressive treatment in multiple sclerosis, pp 219–225Google Scholar
  42. 42.
    Walker JE, Albers JW, Tourtellotte WW, Henderson WG, Potvin AR, Smith A (1972a) A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson’s disease. J Chronic Dis 25(1):149–182PubMedCrossRefGoogle Scholar
  43. 43.
    Walker JE, Potvin AR, Tourtellotte WW, Albers JW, Repa BS, Henderson WG, Snyder DN (1972b) Amantadine and levodopa in the treatment of Parkinson’s disease. Clin Pharmacol Ther 13(1):28–36PubMedGoogle Scholar
  44. 44.
    Watts R (1992) An electrophysiological test battery to aid in the early diagnosis of Parkinsonism. Oral presentation at Second International Congress of Movement Disorders: Satellite Symposium Instrumental methods and scoring in diagnosis and quantification of extrapyramidal disorders, Prien/Chiemsee June 21–22, 1992Google Scholar
  45. 45.
    Winer BJ (1962) Statistical principles in experimental design. McGraw-Hill, New YorkCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • A. R. Potvin
  • W. W. Tourtellotte
  • G. V. Kondraske
  • K. Syndulko
  • J. H. Potvin

There are no affiliations available

Personalised recommendations